AstraZeneca: Deutsche Bank returns to 'Hold'

(CercleFinance.com) - Deutsche Bank announced on Tuesday that it had upgraded its recommendation on AstraZeneca shares to 'hold', just over two months after downgrading it to 'sell'.


In a research note, the broker looks back on the unexpected dividend increase announced by the biopharmaceutical group last week, ahead of the publication of Q1 results and an investor day in May.

While acknowledging that he still has a number of questions about the laboratory's innovation policy and its costly acquisition strategy, DB says he cannot deny that several important catalysts are on the horizon for 2025, which leads it to raise its target price from 9,500 pence to 10,500 pence.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.